• FDA approves expanded use for GSK’s COPD triple therapy pharmaphorum
    April 26, 2018
    The FDA has approved an expanded label for GlaxoSmithKline’s new Trelegy Ellipta inhaler, allowing it to be used in a broader population of patients with chronic obstructive pulmonary disease (COPD).
PharmaSources Customer Service